Morales, Clarissa D.
Cotton-Samuel, Dejania
Lao, Patrick J.
Chang, Julia F.
Pyne, Jeffrey D.
Alshikho, Mohamad J.
Lippert, Rafael V.
Bista, Kelsang
Hale, Christiane
Edwards, Natalie C.
Igwe, Kay C.
Deters, Kacie
Zimmerman, Molly E.
Brickman, Adam M.
Funding for this research was provided by:
National Institutes of Health
Article History
Received: 11 September 2023
Accepted: 21 January 2024
First Online: 2 February 2024
Declarations
:
: This study is a secondary data analysis of a publicly available dataset from the screening visit of the A4 trial. The A4 trial received ethics approval by Institutional Review Boards in accordance with International Council for Harmonisation Good Clinical Practice guidelines at each of the 67 trial sites in Australia, Canada, Japan, and the USA, and all participants gave written informed consent.
: Not applicable.
: Dr. Brickman is an inventor on a patent for quantification of white matter hyperintensities. He is a scientific advisor for Cognition Therapeutics, Inc; CogState; and Cognito Therapeutics, Inc.